These 3 Biotechs Have Different Approaches To A COVID-19 Vaccine, But The Same Analyst Rating: ‘Buy’

An intranasal vaccine, an mRNA vaccine, and a T-cell activation vaccine: the three biotech companies discussed in today’s article are approaching the virus that causes COVID-19 from different directions, but they have in common ‘Buy’ ratings from one investment banking firm that sees significant upside potential for each, as well as overall bullish sentiment from the broader analyst community. For more on these three COVID-19 vaccine stocks, CLICK HERE.